+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-03-31Number of Pages: 171

Prostate Cancer Therapeutics Market (Therapy Type - Hormone Therapy {Luteinizing Hormone-Releasing Hormone Analogs, Luteinizing Hormone-Releasing Hormone Antagonists, and Antiandrogens}, Chemotherapy {Systemic Chemotherapy and Regional Chemotherapy}, Biologic Therapy, and Targeted Therapy); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Prostate Cancer Therapeutics Market: Snapshot

Prostate cancer is a serious health issue among men and has a large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is the fourth-most common cancer diagnosed globally. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual.

Approximately 75% of prostate cancers are developed sporadically, in which genetic changes occur after birth. Although, the real cause of prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight, and past history of certain cancers. The global prostate cancer therapeutics market was valued at US$8.78 bn in 2015. Rising at a CAGR of 8.1% between 2016 and 2024, the market is expected to reach US$17.53 bn by the end of 2025. The overall market is segmented on the basis of therapy type, and distribution channel segments. global prostate cancer therapeutics market

Hormone Therapy to Remain Dominant Segment Based on Therapy Type

Based on therapy type, the global prostate cancer therapeutics market is segmented into hormone therapy, chemotherapy, biologic therapy, and targeted therapy. Of these, the hormone therapy segment dominated global prostate cancer therapeutics market with a share of 82.7% in 2015. Hormone therapy offers excellent efficacy in castration resistant prostate cancer patients, which is a chief factor fuelling its demand in the treatment of prostate cancer patients. The dominance of the segment is thus forecast to remain unaffected through the forecast period.

Besides this, the targeted therapy segment is anticipated to gain market share during forecast period due to expected new product launches in this segment. The biologic therapy segment is expected to have a moderate market share and is likely to expand with a high CAGR during the forecast period due to introduction of novel therapy products in prostate cancer therapeutics market and increase in prevalence of prostate cancer globally.

Based on distribution channel, the global prostate cancer therapeutics market is segmented into hospital pharmacy, online sales, retail pharmacy, and others. Of these, the hospital pharmacy segment emerged dominant in 2015. The segment is gaining momentum on account of the rising incidence of prostate cancer around the world and advancements in diagnosis techniques. As an increasing number of patients seek medical care in hospitals, the hospital pharmacy segment will witness accelerated pace of gains in response. In addition, the online sales segment is forecast to witness significant growth over the forecast period. This segment will gain from the rising use of mobile based applications for placing online orders for medicines.

North America and Europe Cumulatively Hold Leading Market Share

Regionally, North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa constitute the key segments in the global prostate cancer therapeutics market. Among these, North America and Europe cumulatively held the leading market share in 2015. This trend is likely to continue through the forecast period. While in 2015, North America emerged dominant holding a marginally higher share of 39.8% as compared to Europe, in the coming years the table is expected to turn in favor of Europe.

The rising diseased population and a sophisticated healthcare infrastructure will support growth of the prostate cancer therapeutics market in North America and Europe. Besides this, Asia Pacific and Latin America are expected to emerge as promising market owing to the increasing awareness about prostate cancer and the available treatment and diagnosis options. The rising healthcare spending will also support the market’s expansion in Asia Pacific and Latin America.

Pfizer, Inc. dominated the global prostate cancer therapeutics market in 2015. Major factors attributed to its dominance are acquisition of leading brand, and widespread market presence. Other players in the global prostate cancer therapeutics market include Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., Dendreon Corporation (Sanpower Group Co. Ltd.) and others

Global Prostate Cancer Therapeutics Market: Overview

This report on the prostate cancer therapeutics market analyzes the current and future scenario of the global market. Increasing prevalence of prostate cancer, launch of promising emerging therapies, as well as innovation in the development of new drugs & therapeutic biological products, and high growth in hormone-refractory prostate cancer drug due to lesser side effects are some of the drivers expected to drive the global prostate cancer therapeutics market during the forecast period.

The global prostate cancer therapeutics market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the country’s market with respect to the segments based on therapy type, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global prostate cancer therapeutics market.

Global Prostate Cancer Therapeutics Market: Key Segments

Based on therapy type, the market has been segmented into hormone therapy, chemotherapy, biologic therapy and targeted therapy. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference from oncologists for treating the prostate cancer with various drug classes. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on distribution channels, the global prostate cancer therapeutics market has been segmented into hospital pharmacy, retail pharmacy, online sales and others. The market segments have been extensively analyzed based on increase in demand for disease treatment among prostate cancer patients. Increased patient hospitalization for the treatment of prostate cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Global Prostate Cancer Therapeutics Market: Regional Outlook

Geographically, the global prostate cancer therapeutics market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Companies Mentioned in Report

The report also profiles major players in the global prostate cancer therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include players in the global prostate cancer therapeutics market are Amgen, Inc., Johnson & Johnson (Janssen Biotech, Inc.), Pfizer, Inc., AstraZeneca, AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., Dendreon Corporation (Sanpower Group Co. Ltd.) and others.

The Global Prostate Cancer Therapeutics Market is segmented as given below:

Global Prostate Cancer Therapeutics Market, by Therapy

  • Hormone Therapy
    • Luteinizing Hormone-Releasing Hormone Analogs
    • Luteinizing Hormone-Releasing Hormone Antagonists
    • Antiandrogens
  • Chemotherapy
    • Systemic Chemotherapy
    • Regional Chemotherapy
  • Biologic Therapy
  • Targeted Therapy

Global Prostate Cancer Therapeutics Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Others

Global Prostate Cancer Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East & Africa


 
 
Back To Top